Complete regression of subcutaneous and cutaneous metastatic melanoma with high-dose intralesional interleukin 2 in combination with topical imiquimod and retinoid cream

Melanoma Research

Volumn 21, Issue 3, 2011, Pages 235-243

  Garcia, Miki Shirakawa ^a   Ono, Yoko ^a   Martinez, Steve R ^a   Chen, Steven L ^a   Goodarzi, Heidi ^a   Phan, Tiffany ^a   Wehrli, Lisa N ^a   Miyamura, Yoshinori ^a   Fung, Maxwell A ^a   Maverakis, Emanual ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Northern California Health Care System   (United States)

Author keywords

imiquimod; immunotherapy; inflammation; interleukin 2; intralesional therapy; melanoma; retinoic acid; toll like receptors

Indexed keywords

ALPHA2B INTERFERON; IMIQUIMOD; RECOMBINANT INTERLEUKIN 2; RETINOIC ACID; RETINOID; TAZAROTENE;

ADULT; AGED; ARTHRALGIA; ARTICLE; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CASE REPORT; CHILL; CREAM; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHEMA; FATIGUE; HUMAN; INJECTION PAIN; LYMPH NODE METASTASIS; MALE; MELANOMA; PRIORITY JOURNAL; SCAR; SCAR FORMATION; SCLERODERMA; SIDE EFFECT; SKIN ULCER; TREATMENT RESPONSE; TUMOR BIOPSY; WEIGHT REDUCTION;

ADMINISTRATION, TOPICAL; AGED, 80 AND OVER; AMINOQUINOLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; INJECTIONS, INTRALESIONAL; INTERLEUKIN-2; MALE; MELANOMA; MIDDLE AGED; RETINOIDS; SKIN NEOPLASMS;

EID: 79955592285     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e328345e95e     Document Type: Article

References (38)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59:225-249.
2. Maverakis E, Miyamura Y, Bowen MP, Correa G, Ono Y, Goodarzi H. Light, including ultraviolet. J Autoimmun 2010; 34:J247-J257.
3. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999; 17:2105-2116. (Pubitemid 29318842)
4. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298:850-854. (Pubitemid 35231542)
5. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.
6. Proctor JW, Zidar B, Pomerantz M, Yamamura Y, Eng CP, Woodside D. Anaphylactic reaction to intralesional B.C.G. Lancet 1978; 2:162.
7. Gothelf A, Mir LM, Gehl J. Electrochemotherapy: results of cancer treatment using enhanced delivery of bleomycin by electroporation. Cancer Treat Rev 2003; 29:371-387. (Pubitemid 37185104)
8. Irie RF, Morton DL. Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2. Proc Natl Acad Sci USA 1986; 83:8694-8698. (Pubitemid 17194932)
9. Green DS, Bodman-Smith MD, Dalgleish AG, Fischer MD. Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma. Br J Dermatol 2007; 156:337-345. (Pubitemid 46095963)
10. Turza K, Dengel LT, Harris RC, Patterson JW, White K, Grosh WW, Slingluff CL Jr. Effectiveness of imiquimod limited to dermal melanoma metastases, with simultaneous resistance of subcutaneous metastasis. J Cutan Pathol 2009. [Epub 19602071].
11. Radny P, Caroli UM, Bauer J, Paul T, Schlegel C, Eigentler TK, et al. Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. Br J Cancer 2003; 89:1620-1626. (Pubitemid 37464130)
12. Loquai C, Nashan D, Metze D, Beiteke U, Ruping KW, Luger TA, et al. Imiquimod, pegylated interferon-alpha-2b and interleukin-2 in the treatment of cutaneous melanoma metastases. Hautarzt 2004; 55:176-181. (Pubitemid 38391406)
13. Pfohler C, Steinhauser S, Wagner A, Ugurel S, Tilgen W. [Complete remission of cutaneous satellite and in-transit metastases: after intralesional therapy with interleukin-2 in 2 patients with malignant melanoma. Hautarzt 2004; 55:171-175. (Pubitemid 38391405)
14. Ridolfi L, Ridolfi R, Ascari-Raccagni A, Fabbri M, Casadei S, Gatti A, et al. Intralesional granulocyte-monocyte colony-stimulating factor followed by subcutaneous interleukin-2 in metastatic melanoma: a pilot study in elderly patients. J Eur Acad Dermatol Venereol 2001; 15:218-223. (Pubitemid 32903899)
15. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002; 3:196-200. (Pubitemid 34141451)
16. Gorden KB, Gorski KS, Gibson SJ, Kedl RM, Kieper WC, Qiu X, et al. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immunol 2005; 174:1259-1268.
17. Beutner KR, Geisse JK, Helman D, Fox TL, Ginkel A, Owens ML. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol 1999; 41:1002-1007.
18. Mackenzie-Wood A, Kossard S, de Launey J, Wilkinson B, Owens ML. Imiquimod 5% cream in the treatment of Bowen's disease. J Am Acad Dermatol 2001; 44:462-470. (Pubitemid 32199966)
19. Edwards L, Ferenczy A, Eron L, Baker D, Owens ML, Fox TL, et al. Self-administered topical 5% imiquimod cream for external anogenital warts. HPVstudy group. Human PapillomaVirus. Arch Dermatol 1998; 134:25-30. (Pubitemid 28087109)
20. Suchin KR, Junkins-Hopkins JM, Rook AH. Treatment of stage IA cutaneous T-cell lymphoma with topical application of the immune response modifier imiquimod. Arch Dermatol 2002; 138:1137-1139. (Pubitemid 35025683)
21. Deeths MJ, Chapman JT, Dellavalle RP, Zeng C, Aeling JL. Treatment of patch and plaque stage mycosis fungoides with imiquimod 5% cream. J Am Acad Dermatol 2005; 52:275-280.
22. Zampogna JC, Flowers FP, Roth WI, Hassenein AM. Treatment of primary limited cutaneous extramammary Paget's disease with topical imiquimod monotherapy: two case reports. J Am Acad Dermatol 2002; 47:S229-S235.
23. Ahmed I, Berth-Jones J. Imiquimod: a novel treatment for lentigo maligna. Br J Dermatol 2000; 143:843-845.
24. Steinmann A, Funk JO, Schuler G, Von den Driesch P. Topical imiquimod treatment of a cutaneous melanoma metastasis. J Am Acad Dermatol 2000; 43:555-556. (Pubitemid 30666755)
25. Naylor MF, Crowson N, Kuwahara R, Teague K, Garcia C, Mackinnis C, et al. Treatment of lentigo maligna with topical imiquimod. Br J Dermatol 2003; 149 (Suppl 66):66-70.
26. Bong AB, Bonnekoh B, Franke I, Schon MP, Ulrich J, Gollnick H. Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma. Dermatology 2002; 205:135-138.
27. Suzuki H, Wang B, Shivji GM, Toto P, Amerio P, Tomai MA, et al. Imiquimod, a topical immune response modifier, induces migration of langerhans cells. J Invest Dermatol 2000; 114:135-141. (Pubitemid 30195986)
28. Burns RP Jr, Ferbel B, Tomai M, Miller R, Gaspari AA. The imidazoquinolines, imiquimod and R-848, induce functional, but not phenotypic, maturation of human epidermal Langerhans' cells. Clin Immunol 2000; 94:13-23. (Pubitemid 30026907)
29. Gibson SJ, Lindh JM, Riter TR, Gleason RM, Rogers LM, Fuller AE, et al. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell Immunol 2002; 218:74-86. (Pubitemid 36027092)
30. Schon MP, Wienrich BG, Drewniok C, Bong AB, Eberle J, Geilen CC, et al. Death receptor-independent apoptosis in malignant melanoma induced by the small-molecule immune response modifier imiquimod. J Invest Dermatol 2004; 122:1266-1276. (Pubitemid 38651103)
31. Dusza SW, Delgado R, Busam KJ, Marghoob AA, Halpern AC. Treatment of dysplastic nevi with 5% imiquimod cream, a pilot study. J Drugs Dermatol 2006; 5:56-62.
32. Chambon P. A decade of molecular biology of retinoic acid receptors. FASEB J 1996; 10:940-954. (Pubitemid 26285969)
33. Mucida D, Park Y, Kim G, Turovskaya O, Scott I, Kronenberg M, et al. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science 2007; 317:256-260. (Pubitemid 47076203)
34. Green DS, Dalgleish AG, Belonwu N, Fischer MD, Bodman-Smith MD. Topical imiquimod and intralesional interleukin-2 increase activated lymphocytes and restore the Th1/Th2 balance in patients with metastatic melanoma. Br J Dermatol 2008; 159:606-614.
35. Demaria S, Ng B, Devitt ML, Babb JS, Kawashima N, Liebes L, et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys 2004; 58:862-870. (Pubitemid 38221143)
36. Sercarz EE, Maverakis E. Mhc-guided processing: binding of large antigen fragments. Nat Rev Immunol 2003; 3:621-629. (Pubitemid 37328665)
37. Maverakis E, Goodarzi H, Wehrli LN, Ono Y, Garcia MS. The etiology of paraneoplastic autoimmunity. Clin Rev Allergy Immunol 2011. [Epub 21246308].
38. Maverakis E, Beech J, Stevens DB, Ametani A, Brossay L, van den Elzen P, et al. Autoreactive Tcells can be protected from tolerance induction through competition by flanking determinants for access to class II MHC. Proc Natl Acad Sci USA 2003; 100:5342-5347. (Pubitemid 36542707)